Cancer treatment

On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine.   This report chronicles how basic, translational, clinical cancer research, and cancer-related population sciences — supported by federal investments in the National Institutes of Health (NIH) and the National Cancer […]

GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single […]

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’ medicines manufacturing unit. In a statement, Sciensus said that it was an […]

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and published in The Lancet. Biliary tract cancers are rare […]

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN clinical trial were presented at the AACR Annual Meeting […]

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023, held April 14-19. The mainstays of curative therapies for […]

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, […]

This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer   Advances and challenges in cancer drug discovery   The ‘dark matter’ behind cancer  The drug that may […]

This latest eBook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer   Advances and challenges in cancer drug discovery   The ‘dark matter’ behind cancer  The drug that may […]

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. The study shows how a breakthrough drug called CADD522 blocks a gene associated with driving the cancer’s spread in mice implanted with human bone cancer. The drug increases survival rates by […]

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In China, there were nearly 86,000 new cases of bladder cancer […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments […]

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments in cancer drug discovery this week. Most notably, a 20-year mystery regarding the ‘dark matter’ of the […]

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.  Spearheading the new Lancet Oncology Commission focused on cancer genomics and precision oncology, Glasgow researchers will lead an international team of experts over the next two years to create a blueprint […]

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and beginning to understand the underlying […]

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, which occurs […]